AAI President Diana Moss is one of five competition scholars honored in the Global Competition Review's 2016 Women in Antitrust (Academics).
The full list of speakers is in for AAI’s 2016 Airline Roundtable - The Changing Airline Competition Agenda. Experts in antitrust and regulation from government, industry, advocacy, and academia will discuss major competition issues facing the airline industry and consumers of air travel on December 14 in Washington DC.
In comments to the Federal Energy Regulatory Commission in Docket RM16-21, the AAI offered suggestions on how the Commission can update and improve its analysis of competitive issues in electric utility merger applications and requests for market-based rate authority.
On February 8, 2017, the American Antitrust Institute (AAI) hosted an International Antitrust Roundtable where experts from business, academia, law, and government in the U.S. and abroad gathered to discuss major competition enforcement and policy issues on the global antitrust agenda.
AAI President Diana Moss recently delivered remarks at two industry conferences on healthcare. Moss spoke on consolidation in the health insurance industry at the Colorado Medical Society annual meeting on October 24 in Denver.
On December 14, the American Antitrust Institute will host its second annual Airline Roundtable. Experts in antitrust and regulation from government, industry, advocacy, and academia will discuss major competition issues facing the airline industry and consumers of air travel. This year's Roundtable will focus on challenges to competition, with the goal of focusing antitrust and regulatory aviation policies to promote rivalry, innovation, and consumer benefits.
On November 7, the Supreme Court declined to review the Third Circuit’s holding in SmithKline Beecham Corp. v. King Drug Co. of Florence, Inc. that a brand drug’s promise to refrain from selling an “authorized generic” could constitute an unlawful payment in exchange for the generic’s agreement to delay entry. Such “no-AG” promises are a common form of pay-for-delay agreements that substantially raise drug prices. In an amicus brief, the American Antitrust Institute (AAI) had urged the Third Circuit to reject the district court’s holding that a reverse payment was not subject to antitrust scrutiny unless it included a cash payment.
In the wake of the presidential election, there is uncertainty over what the next four years will mean for the enforcement of our antitrust laws.
Jonathan B. Baker delivered the keynote address at the AAI's 10th Annual Private Enforcement Conference.
The American Antitrust Institute (AAI) recognized leading legal practitioners and economists at the AAI 2016 Antitrust Enforcement Awards.